The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Riociguat for the Treatment of Pulmonary Arterial Hypertension
Open accessAbstract
Background Riociguat, a soluble guanylate cyclase stimulator, has been shown in a phase 2 trial to be beneficial in the treatment of pulmonary arterial hypertension. Methods In this phase 3, double-blind study, we randomly assigned 443 patients with symptomatic pulmonary arterial hypertension to receive placebo, riociguat in individually adjusted doses of up to 2.5 mg three times daily (2.5 mg-maximum group), or riociguat in individually adjusted doses that were capped at 1.5 mg three times daily (1.5 mg-maximum group). The 1.5 mg-maximum group was included for exploratory purposes, and the data from that group were analyzed descriptively. Patients who were receiving no other treatment for pulmonary arterial hypertension and patients who were receiving endothelin-receptor antagonists or (nonintravenous) prostanoids were eligible. The primary end point was the change from baseline to the end of week 12 in the distance walked in 6 minutes. Secondary end points included the change in pulmonary vascular resistance, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, World Health Organization (WHO) functional class, time to clinical worsening, score on the Borg dyspnea scale, quality-of-life variables, and safety. Results By week 12, the 6-minute walk distance had increased by a mean of 30 m in the 2.5 mg-maximum group and had decreased by a mean of 6 m in the placebo group (least-squares mean difference, 36 m; 95% confidence interval, 20 to 52; P Conclusions Riociguat si…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Given that most efficacious therapies for the treatment of PH involve targeting of NO signaling[48,49], it is clear that pulmonary vascular health is intimately tied to effective NO bioactivity.”
From Enterosalivary nitrate metabolism and the microbiome: Intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health (2017) · cites this paper as [49]
Citations
Cites
Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Hoeper, M. M., Humbert, M. J. C., Torbicki, A., Vachiéry, J., Barberà, J. A., Beghetti, M., Corris, P. A., Gaine, S., Gibbs, J. S. R., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp297 · Cited by 3,853
Self-citationBosentan Therapy for Pulmonary Arterial Hypertension
Rubin, L. J., Badesch, D. B., Barst, R. J., Galiè, N., Black, C. M., KEOGH, A. M., Pulido, T., Frost, A., Roux, S., Leconte, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012212 · Cited by 2,718
Self-citationBarst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. Μ., Tapson, V. F., Bourge, R. C., Brundage, B. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340504 · Cited by 2,688
Self-citationSildenafil Citrate Therapy for Pulmonary Arterial Hypertension
Galiè, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D. B., Fleming, T. R., Parpia, T., Burgess, G., Branzi, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050010 · Cited by 2,466
Self-citationACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M., Rosenson, R. S., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.01.004 · Cited by 2,359
Self-citationInhaled Iloprost for Severe Pulmonary Hypertension
Olschewski, H., Simonneau, G., Galiè, N., HIGENBOTTAM, T. W., Naeije, R., Rubin, L. J., Nikkho, S. M., Speich, R., Hoeper, M. M., Behr, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020204 · Cited by 1,783
Self-citationRiociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
Ghofrani, H. A., D’Armini, A. M., Grimminger, F., Hoeper, M. M., Jansa, P., Kim, N. H., Mayer, E., Simonneau, G., Wilkins, M. R., Fritsch, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209657 · Cited by 1,393
Self-citationMiyamoto, S., Nagaya, N., Satoh, T., Kyotani, S., Sakamaki, F., Fujita, M., Nakanishi, N., & Miyatake, K. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.9906015 · Cited by 1,147
Benza, R. L., Miller, D. P., Barst, R. J., Badesch, D. B., Frost, A., & McGoon, M. D. (2012) · CHEST Journal · doi:10.1378/chest.11-1460 · Cited by 1,107
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M., Rosenson, R. S., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192230 · Cited by 1,096
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Self-citation2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Humbert, M. J. C., Kovács, G., Hoeper, M. M., Badagliacca, R., Berger, R. M. F., Brida, M., Carlsen, J., Coats, A. J. S., Subías, P. E., Ferrari, P., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac237 · Cited by 4,286
Self-citation2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M. J. C., Vachiéry, J., Gibbs, S., Lang, I. M., Torbicki, A., Simonneau, G., Peacock, A. J., Noordegraaf, A. V., Beghetti, M., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01032-2015 · Cited by 3,198
Self-citation2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Humbert, M. J. C., Kovács, G., Hoeper, M. M., Badagliacca, R., Berger, R. M. F., Brida, M., Carlsen, J., Coats, A. J. S., Subías, P. E., Ferrari, P., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.00879-2022 · Cited by 2,388
Self-citationInitial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
Galiè, N., Barberà, J. A., Frost, A., Ghofrani, H. A., Hoeper, M. M., McLaughlin, V. V., Peacock, A. J., Simonneau, G., Vachiéry, J., Grünig, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413687 · Cited by 1,182
Self-citationOparil, S., Acelajado, M. C., Bakris, G. L., Berlowitz, D. R., Cífková, R., Dominiczak, A. F., Grassi, G., Jordan, J., Poulter, N. R., Rodgers, A., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.14 · Cited by 1,167
Update of EULAR recommendations for the treatment of systemic sclerosis
Kowal-Bielecka, O., Fransen, J., Avouac, J., Becker, M., Kulak, A., Allanore, Y., Distler, O., Clements, P., Cutolo, M., Czirjak, L., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209909 · Cited by 1,104
Selexipag for the Treatment of Pulmonary Arterial Hypertension
Sitbon, O., Channick, R. N., Chin, K., Frey, A., Gaine, S., Galiè, N., Ghofrani, H. A., Hoeper, M. M., Lang, I. M., Preiss, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503184 · Cited by 1,062
Self-citationPulmonary arterial hypertension: pathogenesis and clinical management
Thenappan, T., Ormiston, M. L., Ryan, J. J., & Archer, S. L. (2018) · BMJ · doi:10.1136/bmj.j5492 · Cited by 1,004
Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap
Shah, S. J., Kitzman, D. W., Borlaug, B. A., van Heerebeek, L., Zile, M. R., Kass, D. A., & Paulus, W. J. (2016) · Circulation · doi:10.1161/circulationaha.116.021884 · Cited by 1,003
Risk stratification and medical therapy of pulmonary arterial hypertension
Galiè, N., Channick, R. N., Frantz, R. P., Grünig, E., Jing, Z. C., Moiseeva, O., Preston, I. R., Pulido, T., Safdar, Z., Tamura, Y., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01889-2018 · Cited by 819
Self-citationDiagnosis and Treatment of Pulmonary Arterial Hypertension
Ruopp, N. F., & Cockrill, B. A. (2022) · JAMA · doi:10.1001/jama.2022.4402 · Cited by 682
Pulmonary Hypertension in Chronic Lung Diseases
Seeger, W., Adir, Y., Barberà, J. A., Champion, H. C., Coghlan, G., Cottin, V., Marco, T. D., Galiè, N., Ghio, S., Gibbs, S., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.036 · Cited by 678
Self-citationUpdated Treatment Algorithm of Pulmonary Arterial Hypertension
Galiè, N., Corris, P. A., Frost, A., Girgis, R. E., Granton, J. T., Jing, Z., Klepetko, W., McGoon, M. D., McLaughlin, V. V., Preston, I. R., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.031 · Cited by 667
Self-citationPulmonary Hypertension Due to Left Heart Diseases
Vachiéry, J., Adir, Y., Barberà, J. A., Champion, H. C., Coghlan, G., Cottin, V., Marco, T. D., Galiè, N., Ghio, S., Gibbs, J. S. R., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.033 · Cited by 631
Self-citationStrategies to increase nitric oxide signalling in cardiovascular disease
Lundberg, J. O., Gladwin, M. T., & Weitzberg, E. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4623 · Cited by 576
Sources of Vascular Nitric Oxide and Reactive Oxygen Species and Their Regulation
Tejero, J., Shiva, S., & Gladwin, M. T. (2019) · Physiological Reviews · doi:10.1152/physrev.00036.2017 · Cited by 541
Brozovich, F. V., Nicholson, C., Degen, C. V., Gao, Y. Z., Aggarwal, M., & Morgan, K. G. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.010652 · Cited by 568
Epidemiology and treatment of pulmonary arterial hypertension
Lau, E., Giannoulatou, E., Celermajer, D. S., & Humbert, M. J. C. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.84 · Cited by 503
Self-citationTargeting vascular (endothelial) dysfunction
Daiber, A., Steven, S., Weber, A., Shuvaev, V. V., Muzykantov, V. R., Laher, I., Li, H., Lamas, S., & Münzel, T. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13517 · Cited by 501
Wigley, F. M., & Flavahan, N. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1507638 · Cited by 443
Ehret, G., Ferreira, T. C., Chasman, D. I., Jackson, A., Schmidt, E. M., Johnson, T., Þorleifsson, G., Luan, J., Donnelly, L. A., Kanoni, S., et al. (2016) · Nature Genetics · doi:10.1038/ng.3667 · Cited by 417
2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension
Galiè, N., Humbert, M. J. C., Vachiéry, J., Gibbs, S., Lang, I. M., Torbicki, A., Simonneau, G., Peacock, A. J., Noordegraaf, A. V., Beghetti, M., et al. (2016) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2016.01.002 · Cited by 373
Self-citationManagement of Pulmonary Arterial Hypertension
McLaughlin, V. V., Shah, S. J., Souza, R., & Humbert, M. J. C. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.540 · Cited by 381
Self-citationBenza, R. L., Kanwar, M. K., Raina, A., Scott, J. V., Zhao, C., Selej, M., Elliott, C. G., & Farber, H. W. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.08.2069 · Cited by 350
Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension
Humbert, M. J. C., Lau, E., Montani, D., Jaïs, X., Sitbon, O., & Simonneau, G. (2014) · Circulation · doi:10.1161/circulationaha.114.006974 · Cited by 352
Self-citationPulmonary arterial hypertension
Montani, D., Günther, S., Dorfmüller, P., Perros, F., Girerd, B., Garcia, G., Jaïs, X., Savale, L., Artaud-Macari, É., Price, L., et al. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-97 · Cited by 355
Self-citationThe Metabolic Theory of Pulmonary Arterial Hypertension
Paulin, R., & Michelakis, E. D. (2014) · Circulation Research · doi:10.1161/circresaha.115.301130 · Cited by 328
Simonneau, G., D’Armini, A. M., Ghofrani, H. A., Grimminger, F., Hoeper, M. M., Jansa, P., Kim, N. H., Wang, C., Wilkins, M. R., Fritsch, A., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00087114 · Cited by 312
Self-citationEULAR recommendations for the treatment of systemic sclerosis: 2023 update
Galdo, F. D., Lescoat, A., Conaghan, P. G., Bertoldo, E., Colic, J., Santiago, T., Suliman, Y. A., Matucci‐Cerinic, M., Gabrielli, A., Distler, O., et al. (2024) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2024-226430 · Cited by 318
Treatment algorithm for pulmonary arterial hypertension
Chin, K., Gaine, S., Gerges, C., Jing, Z., Mathai, S. C., Tamura, Y., McLaughlin, V. V., & Sitbon, O. (2024) · European Respiratory Journal · doi:10.1183/13993003.01325-2024 · Cited by 275
Self-citationBonderman, D., Pretsch, I., Steringer‐Mascherbauer, R., Jansa, P., Rosenkranz, S., Tufaro, C., Bojic, A., Lam, C. S. P., Frey, R., Kilama, M. O., et al. (2014) · CHEST Journal · doi:10.1378/chest.14-0106 · Cited by 258
Self-citationNathan, S. D., Behr, J., Collard, H. R., Cottin, V., Hoeper, M. M., Martínez, F. J., Corte, T. J., KEOGH, A. M., Leuchte, H. H., Moğulkoç, N., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30250-4 · Cited by 256
Self-citationKapil, V., Khambata, R. S., Jones, D. A., Rathod, K., Primus, C., Massimo, G., Fukuto, J. M., & Ahluwalia, A. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019240 · Cited by 248
Chang, K. Y., Duval, S., Badesch, D. B., Bull, T. M., Chakinala, M. M., Marco, T. D., Frantz, R. P., Hemnes, A. R., Mathai, S. C., Rosenzweig, E. B., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.024969 · Cited by 244
Nitric oxide: what’s new to NO?
Ghimire, K., Altmann, H. M., Straub, A. C., & Isenberg, J. S. (2016) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00315.2016 · Cited by 241
Guía ESC/ERS 2015 sobre diagnóstico y tratamiento de la hipertensión pulmonar
Galiè, N., Humbert, M. J. C., Vachiéry, J., Gibbs, S., Lang, I. M., Torbicki, A., Simonneau, G., Peacock, A. J., Noordegraaf, A. V., Beghetti, M., et al. (2016) · Revista Española de Cardiología · doi:10.1016/j.recesp.2016.01.002 · Cited by 240
Self-citationPulmonary hypertension in bronchopulmonary dysplasia
Hansmann, G., Sallmon, H., Roehr, C. C., Kourembanas, S., Austin, E. D., Köestenberger, M., & for the European Pediatric Pulmonary Vascular Disease Network (EPPVDN) (2020) · Pediatric Research · doi:10.1038/s41390-020-0993-4 · Cited by 238
Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis
Lajoie, A. C., Lauzière, G., Lega, J., Lacasse, Y., Martin, S., Simard, S., Bonnet, S., & Provencher, S. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)00027-8 · Cited by 234
Guidelines for the Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017)
Fukuda, K., Date, H., Doi, S., Fukumoto, Y., Fukushima, N., Hatano, M., Ito, H., Kuwana, M., Matsubara, H., Momomura, S., et al. (2019) · Circulation Journal · doi:10.1253/circj.cj-66-0158 · Cited by 231
Rubin, L. J., Galiè, N., Grimminger, F., Grünig, E., Humbert, M. J. C., Jing, Z., KEOGH, A. M., Langleben, D., Fritsch, A., Menezes, F., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00090614 · Cited by 221
Self-citationFollmann, M., Ackerstaff, J., Redlich, G., Wunder, F., Lang, D. H., Kern, A., Fey, P., Griebenow, N., Kroh, W., Becker‐Pelster, E., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00449 · Cited by 210
Armstrong, P. W., Roessig, L., Patel, M. J., Anstrom, K. J., Butler, J., Voors, A. A., Lam, C. S. P., Ponikowski, P. P., Temple, T., Pieske, B. M., et al. (2017) · JACC Heart Failure · doi:10.1016/j.jchf.2017.08.013 · Cited by 210
The Role of Nitroglycerin and Other Nitrogen Oxides in Cardiovascular Therapeutics
Divakaran, S., & Loscalzo, J. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.1064 · Cited by 218
The Chemistry and Biology of Soluble Guanylate Cyclase Stimulators and Activators
Follmann, M., Griebenow, N., Hahn, M. G., Hartung, I., Mais, F., Mittendorf, J., Schäfer, M., Schirok, H., Stasch, J., Stoll, F., et al. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201302588 · Cited by 200
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis
Hoeper, M. M., Dwivedi, K., Pausch, C., Lewis, R. A., Olsson, K. M., Huscher, D., Pittrow, D., Grünig, E., Staehler, G., Vizza, C. D., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00097-2 · Cited by 197
Self-citationClinical trial design and new therapies for pulmonary arterial hypertension
Sitbon, O., Gomberg‐Maitland, M., Granton, J. T., Lewis, M. I., Mathai, S. C., Rainisio, M., Stockbridge, N., Wilkins, M. R., Zamanian, R. T., & Rubin, L. J. (2018) · European Respiratory Journal · doi:10.1183/13993003.01908-2018 · Cited by 196
Self-citationPulmonary arterial hypertension: the burden of disease and impact on quality of life
Delcroix, M., & Howard, L. (2015) · European Respiratory Review · doi:10.1183/16000617.0063-2015 · Cited by 198
Pulmonary Arterial Hypertension: Pathophysiology and Treatment
Lan, N. S. H., Massam, B. D., Kulkarni, S. S., & Lang, C. C. (2018) · Diseases · doi:10.3390/diseases6020038 · Cited by 188
Poch, D. S., & Mandel, J. (2021) · Annals of Internal Medicine · doi:10.7326/aitc202104200 · Cited by 190
Koch, C. D., Gladwin, M. T., Freeman, B. A., Lundberg, J. O., Weitzberg, E., & Morris, A. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.12.015 · Cited by 186
Galiè, N., Müller, K., Scalise, A., & Grünig, E. (2015) · European Respiratory Journal · doi:10.1183/09031936.00105914 · Cited by 186
Self-citationSoluble Guanylate Cyclase Stimulators and Activators
Sandner, P., Zimmer, D. P., Milne, G. T., Follmann, M., Hobbs, A. J., & Stasch, J. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_197 · Cited by 189
Alzheimer?s disease: the impact of age-related changes in reproductive hormones
Meethal, S. V., & Atwood, C. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4381-3 · Cited by 194
Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics
Mintz, J. A., Vedenko, A., Rosete, O. J., Shah, K. H., Goldstein, G., Hare, J. M., Ramasamy, R., & Arora, H. (2021) · Vaccines · doi:10.3390/vaccines9020094 · Cited by 183
Hoeper, M. M., Ghofrani, H.-A., Grünig, E., Klose, H. F. E., Olschewski, H., & Rosenkranz, S. (2017) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2016.0073 · Cited by 177
Self-citationKessler, T., Vilne, B., & Schunkert, H. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506174 · Cited by 180
Soluble Guanylate Cyclase Stimulators in Pulmonary Hypertension
Stasch, J., & Evgenov, O. V. (2013) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-38664-0_12 · Cited by 168
Hoeper, M. M., Al‐Hiti, H., Benza, R. L., Chang, S., Corris, P. A., Gibbs, J. S. R., Grünig, E., Jansa, P., Klinger, J. R., Langleben, D., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30532-4 · Cited by 162
Self-citationPathophysiology and new advances in pulmonary hypertension
Bousseau, S., Fais, R. S., Gu, S., Frump, A. L., & Lahm, T. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2022-000137 · Cited by 171
Suresh, K. S., & Shimoda, L. A. (2016) · Comprehensive physiology · doi:10.1002/cphy.c140049 · Cited by 174
Hoeper, M. M., Simonneau, G., Corris, P. A., Ghofrani, H. A., Klinger, J. R., Langleben, D., Naeije, R., Jansa, P., Rosenkranz, S., Scelsi, L., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.02425-2016 · Cited by 158
Self-citationAutoregulation of Osteocyte Sema3A Orchestrates Estrogen Action and Counteracts Bone Aging
Hayashi, M., Nakashima, T., Yoshimura, N., Okamoto, K., Tanaka, S., & Takayanagi, H. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.12.021 · Cited by 156
Nanchal, R. S., Subramanian, R., Karvellas, C. J., Hollenberg, S. M., Peppard, W. J., Singbartl, K., Truwit, J. D., Al-Khafaji, A. H., Killian, A. J., Alquraini, M., et al. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004192 · Cited by 160
The molecular targets of approved treatments for pulmonary arterial hypertension
Humbert, M. J. C., & Ghofrani, H. A. (2015) · Thorax · doi:10.1136/thoraxjnl-2015-207170 · Cited by 155
Self-citationSotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension
Humbert, M. J. C., McLaughlin, V. V., Gibbs, J. S. R., Gomberg‐Maitland, M., Hoeper, M. M., Preston, I. R., Souza, R., Waxman, A. B., Ghofrani, H. A., Subías, P. E., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.01347-2022 · Cited by 154
Self-citationCombination therapy: the future of management for idiopathic pulmonary fibrosis?
Wuyts, W. A., Antoniou, K. M., Borensztajn, K., Costabel, U., Cottin, V., Crestani, B., Grutters, J. C., Maher, T. M., Poletti, V., Richeldi, L., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70232-2 · Cited by 150
Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry
Hoeper, M. M., Pausch, C., Grünig, E., Staehler, G., Huscher, D., Pittrow, D., Olsson, K. M., Vizza, C. D., Gall, H. J., Distler, O., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.02024-2021 · Cited by 153
Self-citationThe Fifth World Symposium on Pulmonary Hypertension
Galiè, N., & Simonneau, G. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.030 · Cited by 148
Self-citationHumbert, M. J. C., Coghlan, G., Ghofrani, H. A., Grimminger, F., He, J., Riemekasten, G., Vizza, C. D., Boeckenhoff, A., Meier, C., Pena, J. D. O., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-209087 · Cited by 148
Self-citationLong-term safety and efficacy of imatinib in pulmonary arterial hypertension
Frost, A., Barst, R. J., Hoeper, M. M., Chang, H., Frantz, R. P., Fukumoto, Y., Galiè, N., Hassoun, P. M., Klose, H. F. E., Matsubara, H., et al. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2015.05.025 · Cited by 147
Self-citationStructure and Activation of Soluble Guanylyl Cyclase, the Nitric Oxide Sensor
Montfort, W. R., Wales, J. A., & Weichsel, A. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6693 · Cited by 144
Pulmonary hypertension and its management in patients undergoing non‐cardiac surgery
Pilkington, S., Taboada, D., & Martinez, G. C. (2014) · Anaesthesia · doi:10.1111/anae.12831 · Cited by 143
Congenital diaphragmatic hernia-associated pulmonary hypertension
Gupta, V. S., & Harting, M. T. (2019) · Seminars in Perinatology · doi:10.1053/j.semperi.2019.07.006 · Cited by 139
The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction
Greene, S. J., Gheorghiade, M., Borlaug, B. A., Pieske, B. M., Vaduganathan, M., Burnett, J. C. J., Roessig, L., Stasch, J., Solomon, S. D., Paulus, W. J., et al. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000536 · Cited by 141
Pulmonary Hypertension in Sarcoidosis
Baughman, R. P., Engel, P. J., & Nathan, S. D. (2015) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2015.08.011 · Cited by 138
cGMP: a unique 2nd messenger molecule – recent developments in cGMP research and development
Friebe, A., Sandner, P., & Schmidtko, A. (2019) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-019-01779-z · Cited by 139
Regulation and interactions in the activation of cell-associated plasminogen
My�h�nen, H., & Vaheri, A. I. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4230-9 · Cited by 143
Reactive Oxygen-Related Diseases: Therapeutic Targets and Emerging Clinical Indications
Casas, A. I., Dao, V. T.-V., Daiber, A., Maghzal, G. J., Di Lisa, F., Kaludercic, N., Leach, S., Cuadrado, A., Jaquet, V., Seredenina, T., et al. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2015.6433 · Cited by 136
Rationale and Design of The SOluble guanylate Cyclase StimulatoR in HeArT FailurE Studies (SOCRATES)
Pieske, B. M., Butler, J., Filippatos, G. S., Lam, C. S. P., Maggioni, A. P., Ponikowski, P. P., Shah, S. J., Solomon, S. D., Kraigher‐Krainer, E., Samano, E. S. T., et al. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.135 · Cited by 136
Treatment of pulmonary arterial hypertension: recent progress and a look to the future
Humbert, M. J. C., Sitbon, O., Guignabert, C., Savale, L., Boucly, A., Gallant-Dewavrin, M., McLaughlin, V. V., Hoeper, M. M., & Weatherald, J. C. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00264-3 · Cited by 136
Self-citationMechanisms and treatment of pulmonary arterial hypertension
Ghofrani, H. A., Gomberg‐Maitland, M., Zhao, L., & Grimminger, F. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01064-4 · Cited by 134
Self-citationVasculopathy and pulmonary hypertension in sickle cell disease
Potoka, K. P., & Gladwin, M. T. (2014) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00252.2014 · Cited by 135
Evaluation of Macitentan in Patients With Eisenmenger Syndrome
Gatzoulis, M. Α., Landzberg, M. J., Beghetti, M., Berger, R. M. F., Efficace, M., Gesang, S., He, J., Papadakis, K., Pulido, T., Galiè, N., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.033575 · Cited by 130
Self-citationBeyer, C., Zenzmaier, C., Palumbo‐Zerr, K., Mancuso, R., Distler, A., Dees, C., Zerr, P., Huang, J., Maier, C., Pachowsky, M. L., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204508 · Cited by 132
Kholdani, C., Fares, W. H., & Mohsenin, V. (2015) · Pulmonary Circulation · doi:10.1086/679995 · Cited by 127
Maron, B. A., & Galiè, N. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.4471 · Cited by 127
Self-citationThe importance of patient perspectives in pulmonary hypertension
McGoon, M. D., Ferrari, P., Armstrong, I. J., Denis, M., Howard, L., Lowe, G., Mehta, S., Murakami, N., & Wong, B. A. (2018) · European Respiratory Journal · doi:10.1183/13993003.01919-2018 · Cited by 123
Stasch, J., Schlossmann, J., & Hocher, B. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.12.014 · Cited by 123
Hughes, M., & Herrick, A. L. (2016) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2016.04.001 · Cited by 121
Ghofrani, H. A., Grimminger, F., Grünig, E., Huang, Y., Jansa, P., Jing, Z., Kilpatrick, D., Langleben, D., Rosenkranz, S., Menezes, F., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30019-4 · Cited by 121
Self-citationPhenotypic Consequences of a Genetic Predisposition to Enhanced Nitric Oxide Signaling
Emdin, C. A., Khera, A. V., Klarin, D. M., Natarajan, P., Zekavat, S. M., Nomura, A., Haas, M. E., Aragam, K. G., Ardissino, D., Wilson, J. G., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.028021 · Cited by 121
Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial
Souza, R., Badesch, D. B., Ghofrani, H. A., Gibbs, J. S. R., Gomberg‐Maitland, M., McLaughlin, V. V., Preston, I. R., Waxman, A. B., Grünig, E., Kopeć, G., et al. (2023) · European Respiratory Journal · doi:10.1183/13993003.01107-2023 · Cited by 118
Self-citationThe Nitric Oxide Pathway in Pulmonary Vascular Disease
Klinger, J. R., & Kadowitz, P. J. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.06.012 · Cited by 119
Treatment of pulmonary hypertension
Hoeper, M. M., McLaughlin, V. V., Aldalaan, A. M., Satoh, T., & Galiè, N. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00542-1 · Cited by 116
Self-citationRhee, R. L., Gabler, N. B., Sangani, S., Praestgaard, A. H., Merkel, P. A., & Kawut, S. M. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201507-1456oc · Cited by 115
Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure
Breitenstein, S., Roessig, L., Sandner, P., & Lewis, K. S. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_100 · Cited by 115
Congenital diaphragmatic hernia-associated pulmonary hypertension
Harting, M. T. (2017) · Seminars in Pediatric Surgery · doi:10.1053/j.sempedsurg.2017.04.008 · Cited by 112
Pulmonary Hypertension in Congenital Heart Disease
Pascall, E., & Tulloh, R. M. R. (2018) · Future Cardiology · doi:10.2217/fca-2017-0065 · Cited by 112
p38 MAPK Inhibition Improves Heart Function in Pressure-Loaded Right Ventricular Hypertrophy
Kojonazarov, B. K., Novoyatleva, T., Boehm, M., Happé, C. M., Sibinska, Z., Xia, T., Sajjad, A., Luitel, H., Kriechling, P., Posern, G., et al. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2016-0374oc · Cited by 111
Self-citation
Metadata
- Authors
- Ghofrani, H.-A., Galiè, N., Grimminger, F., Grünig, E., Humbert, M., Jing, Z.-C., Keogh, A. M., Langleben, D., Kilama, M. O., Fritsch, A., Neuser, D., & Rubin, L. J.
- Affiliations
- Justus-Liebig-Universität Gießen (DE)
- University of Bologna (IT)
- University Hospital Heidelberg (DE)
- Université Paris-Sud (FR)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- St Vincent's Hospital Sydney (AU)
- Jewish General Hospital (CA)
- Bayer (Italy) (IT)
- Bayer (Germany) (DE)
- University of California San Diego (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-25
- Volume
- 369
- Issue
- 4
- Pages
- 330-340
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2107011819
- Cited by
- 1,346
- References
- 26
- Citations by year
- 2026: 52 · 2025: 70 · 2024: 75 · 2023: 90 · 2022: 98 · 2021: 112 · 2020: 93 · 2019: 85 · 2018: 92 · 2017: 115 · 2016: 145 · 2015: 152 · 2014: 128 · 2013: 32
- FWCI
- 124.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- riociguat, pulmonary arterial hypertension, soluble guanylate cyclase stimulator, 6-minute walk distance, pulmonary vascular resistance, NT-proBNP, WHO functional class, dyspnea, endothelin receptor antagonists, prostanoids, dose adjustment, syncope, exercise capacity, quality of life, drug safety, drug efficacy
- MeSH terms
- Adult, Aged, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Hypertension, Pulmonary, Male, Middle Aged, Peptide Fragments, Prostaglandins, Pyrazoles, Pyrimidines, Quality of Life, Vascular Resistance, Walking, Exercise Tolerance, Natriuretic Peptide, Brain, Endothelin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
